Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clin...(on may involve but are not limited to co...),Health

Date:12/2/2008

on may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to effectively and efficiently manage the planned growth of our operations; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from o
'/>"/>

SOURCE Response Biomedical Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy
2. FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
3. Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governors Plea to Help the States Population in Need
4. Zimbabwean Health Workers Call For Crisis Response
5. TV News Story on Canine Cancer Generates Dog Lover Response - No. 1 Health Issue for Americas 40 Million Dog-Owning Households
6. iMedExchange Responses to Financial Crisis
7. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
8. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
9. Response Biomedical Closes $5.1 Million Financing
10. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
11. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference